drugset / Trial / NCT04591002
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study designed to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage I lung adenocarcinoma.
Timeline
- Start
- 2022-09-11
- Primary completion
- 2027-09-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Osimertinib | Small molecule | 80 mg | Oral |